Leaflet: information for the user
Levodopa/Carbidopa/Entacapona cinfa 100 mg/25 mg/200 mg film-coated tablets
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
This medication contains three active principles (levodopa, carbidopa and entacapona) in a coated tablet. Levodopa/Carbidopa/Entacapona is used to treat Parkinson's disease.
Parkinson's disease is due to low concentration in the brain of a substance called dopamine. Levodopa increases the amount of dopamine and thus reduces the symptoms of Parkinson's disease. Carbidopa and entacapona improve the antiparkinsonian effects of levodopa.
Do not take Levodopa/Carbidopa/Entacapona cinfa if
Warnings and precautions
Consult your doctor or pharmacist before starting to take Levodopa/Carbidopa/Entacapona cinfa.
If you have or have ever had:
Consult your doctor if you are taking:
Consult your doctor if during treatment with Levodopa/Carbidopa/Entacapona:
Inform your doctor if you or your family/caregiver notice that you are developing unusual desires or a tendency to behave in an unusual way in yourself or that you cannot resist the impulse, determination, or temptation to perform certain activities that may harm you or others. These behaviors are called impulse control disorders and may include excessive gaming, eating, or spending, and an abnormally elevated or concerning sexual impulse. Your doctor may need to review your treatment.
Inform your doctor if you, or your family/caregiver, notice that you are developing symptoms similar to addiction, which lead to a desire for large doses of levodopa/carbidopa/entacapone and other medicines used to treat Parkinson's disease.
During prolonged treatment with Levodopa/Carbidopa/Entacapona, your doctor may perform regular laboratory tests.
If you need to undergo surgery, inform your doctor that you are taking this medicine.
Levodopa/Carbidopa/Entacapona cinfa 100 mg/25 mg/200 mg contains lactose.
This medicine contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medicine.
Levodopa/Carbidopa/Entacapona cinfa 100 mg/25 mg/200 mg contains Red 40 (E-129)
This medicine may cause allergic reactions because it contains Red 40 (E129). It may cause asthma, especially in patients allergic to acetylsalicylic acid.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Adults and elderly patients:
Speak with your doctor or pharmacist if you believe the effect of this medication is too intense or too weak, or if you experience possible side effects.
If you take more Levodopa/Carbidopa/Entacapona cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
You may feel dizzy or agitated, that the heart rate is slower or faster than normal, or that the color of your skin, tongue, eyes, or urine changes.
If you forgot to take Levodopa/Carbidopa/Entacapona cinfa
Do not take a double dose to compensate for the missed doses.
If more than 1 hour remains until the next dose:
Take a tablet as soon as you remember, and the next one at the regular time.
If less than 1 hour remains until the next dose:
Take a tablet as soon as you remember, wait 1 hour, and then take another tablet. Continue as usual.
Always allow 1 hour to pass between tablets of this medication, to avoid possible side effects.
If you interrupt the treatment with Levodopa/Carbidopa/Entacapona cinfa
Do not stop taking this medication unless your doctor tells you to. In that case, your doctor may need to adjust the dose of other Parkinson's disease medications, especially levodopa, to ensure sufficient control of your symptoms.
If you stop taking Levodopa/Carbidopa/Entacapona and other Parkinson's disease medications abruptly, you may experience unwanted side effects.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Many can be relieved by adjusting the dose.
If you experience any of these symptoms during treatment with this medicine,contact your doctor immediately:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Rare (may affect up to 1 in 100 people):
Frequency not known (cannot be estimated from available data):
Desire for large doses of Levodopa/Carbidopa/Entacapona exceeding those required to control motor symptoms, known as dopamine dysregulation syndrome.
Some patients experience severe abnormal involuntary movements (dyskinesias), mood changes, or other side effects after taking large doses of Levodopa/Carbidopa/Entacapona.
The following adverse effects have also been reported:
You may experience the following adverse effects:
Inability to resist the urge to perform an action that could be harmful, and which could include:
Inform your doctor if you experience any of these behaviors; they will discuss how to manage or reduce these symptoms.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish Medicines and Medical Devices Agency:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Dispose of the product 175 days after opening the packaging.
Medicines should not be thrown down the drains or in the trash. Deposit the packaging and unused medicines at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medicines. By doing so, you will help protect the environment.
Composition of Levodopa/Carbidopa/Entacapona cinfa
Appearance of the product and content of the container
Biconvex, oblong tablets, pale red in color, engraved with “100” on one face, smooth on the other.
Levodopa/Carbidopa/Entacapona cinfa 100 mg/25 mg/200 mg is available in HDPE bottles with PP child-resistant closures in containers of 100 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) - Spain
Responsible for manufacturing
Teva Pharmaceutical Works Private
Pallagi út 13, 4042
Debrecen
Hungary
Or
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) – Spain
Last review date of this leaflet: October 2023
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
You can access detailed and updated information on this medicine by scanning with your smartphone the QR code included in the leaflet and packaging. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/79647/P_79647.html
QR code to:https://cima.aemps.es/cima/dochtml/p/79647/P_79647.html
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.